Intestinal metabolism and transport of 5-aminosalicylate

被引:0
|
作者
Zhou, SY
Fleisher, D
Pao, LH
Li, C
Winward, B
Zimmermann, EM
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[3] Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to determine the characteristics of intestinal absorption and metabolism of B-aminosalicylic acid (5ASA). Regional perfusions of 5ASA in the anesthetized rat resulted in the appearance of N-acetyl-5-aminosalicylic acid in the intestinal lumen. Lumenal metabolite appearance was proportional to 5ASA permeability, which was 5-fold higher in the jejunum than in the ileum. Intestinal elimination significantly decreases 5ASA absorption at low lumenal drug concentrations and this process is saturated at high drug concentrations. Metabolite levels in intestinal tissue were higher than plasma levels at low perfusion drug concentrations, whereas the reverse was observed at high concentrations. Transport and metabolism of 5ASA was studied in Caco-2 monolayers. At low drug concentrations, 5ASA was preferentially transported in the basolateral (BL) to apical (AP) direction. With 5ASA incubation in either the AP or BL chamber, the N-acetyl metabolite appeared only in the AP compartment. Transport of N-acetyl-5-aminosalicylic acid was also exclusively observed in the BL to AP direction. Clinical data indicate that anti-inflammatory response to oral 5ASA correlates with the amount of BASA delivered to the intestinal tissue. This study shows that at lumenal levels below 200 mu g/ml (concentrations that are typically achieved by controlled release dosage forms), intestinal secretion of 5ASA accounts for more than 50% of the total elimination and can significantly affect tissue levels and, therefore, may be an important factor in determining the response to 5ASA therapy.
引用
收藏
页码:479 / 485
页数:7
相关论文
共 50 条
  • [41] Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease
    Chang, Hui-Chin
    Gau, Shuo-Yan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (10) : 1183 - 1183
  • [42] Synthesis and Characterization of Rare Earth Solid Complexes with Sodium 5-Aminosalicylate
    张秀英
    李书静
    雷雪峰
    马君现
    Journal of Rare Earths, 2005, (02) : 143 - 147
  • [43] Indications for 5-aminosalicylate in inflammatory bowel disease:Is the body of evidence complete?
    Ad A van Bodegraven
    Chris JJ Mulder
    World Journal of Gastroenterology, 2006, (38) : 6115 - 6123
  • [45] A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis
    Liang, Hong-Liang
    Ouyang, Qin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (01) : 114 - 119
  • [46] Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia
    Selinger, Christian P.
    Kemp, Andrew
    Leong, Rupert W. L.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (03) : 329 - 334
  • [47] Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis
    Wiggins, Jon Brendan
    Rajapakse, Ramona
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (10) : 1279 - 1284
  • [48] ACETYLATION OF 5-AMINOSALICYLATE BY HAMSTER COLON ARYLAMINE N-ACETYLTRANSFERASE
    TUCKER, MA
    SMITH, TJ
    JOURNAL OF APPLIED TOXICOLOGY, 1990, 10 (01) : 73 - 74
  • [49] 5-Aminosalicylate Is Not Chemoprophylactic for Colorectal Cancer in IBD: A Population Based Study
    Bernstein, Charles N.
    Nugent, Zoann
    Blanchard, James F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04): : 731 - 736
  • [50] Indications for 5-aminosalicylate in inflammatory bowel disease: Is the body of evidence complete?
    van Bodegraven, Ad A.
    Mulder, Chris J. J.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (38) : 6115 - 6123